Arkansas is currently home to 669 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Little Rock, Jonesboro, Hot Springs and Fayetteville. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
NCT06225596
Recruiting
This is a global, multicenter, randomized, open-label study, with an adaptive design. The main objective of the study is to measure the efficacy and safety of BT8009 (zelenectide pevedotin) as monotherapy and in combination with pembrolizumab in participants with locally advanced or metastatic urothelial cancer (UC). The study includes a dose selection phase followed by an adaptive design continuation. The study is comprised of 2 cohorts. Cohort 1 will include participants who have not received... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Metastatic Urothelial Cancer
Register for Updates
Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children
NCT06070350
Recruiting
The MATIC-2 is a multicenter clinical trial enrolling children who are less than 18 years of age with hemorrhagic shock potentially needing significant blood transfusion. The primary objective of the clinical trial is to determine the effectiveness of Low Titer Group O Whole Blood (LTOWB) compared to component therapy (CT), and Tranexamic Acid (TXA) compared to placebo in decreasing 24-hour all-cause mortality in children with traumatic life threatening hemorrhage.
Gender:
ALL
Ages:
17 years and below
Trial Updated:
03/27/2025
Locations: Arkansas Children's Hospital, Little Rock, Arkansas
Conditions: Hemorrhagic Shock, Trauma Injury
Register for Updates
SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
NCT04647227
Recruiting
Phase IV multi-center, US-centric, open-label, safety study enrolling participants with Hemophilia A or B with inhibitors, 12 years of age and older, who are either on long term prophylactic treatment (e.g., emicizumab) at risk of experiencing a breakthrough bleeding event (BE), or who are not on prophylactic treatment who may need to control a BE.
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
03/26/2025
Locations: Arkansas Center for Bleeding Disorders, Little Rock, Arkansas
Conditions: Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
Register for Updates
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
NCT04398628
Recruiting
In parallel with the growth of American Thrombosis and Hemostasis Network's (ATHN) clinical studies, the number of new therapies for all congenital and acquired hematologic conditions, not just those for bleeding and clotting disorders, is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have yet to demonstrate long-term safety and effectiveness beyond the pivotal trials that led to their approval. In addition, results from... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/26/2025
Locations: Arkansas Center for Bleeding Disorders, Little Rock, Arkansas
Conditions: Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
Register for Updates
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
NCT06143891
Recruiting
This is a parallel, Phase 3, two-arm study for the treatment of newly diagnosed moderate or severe chronic GVHD. The study duration for a participant includes up to 4 weeks for screening; a treatment period until clinically meaningful cGVHD progression (defined as progression requiring addition of new systemic treatment for cGVHD), relapse/recurrence of the underlying disease, participant starts new systemic treatment for cGVHD or experiences an unacceptable toxicity, at the request of the part... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/25/2025
Locations: University of Arkansas for Medical Sciences-Site Number : 8400019, Little Rock, Arkansas
Conditions: Chronic Graft Versus Host Disease
Register for Updates
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
NCT05633602
Recruiting
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Highlands Oncology Group - Fayetteville, Fayetteville, Arkansas
Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Register for Updates
ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study
NCT05596409
Recruiting
The purpose of this study is to evaluate the efficacy and safety of elacestrant over the course of 6 months in patients with estrogen receptor positive (ER+)/human epidermal growth factor receptor-2 negative (HER2-) advanced/metastatic breast cancer who received no prior cyclin-dependent kinase targeting enzymes CDK4 and CDK6 inhibitor (CDK4/6i) in the metastatic setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Highlands Oncology Group, PA, Springdale, Arkansas
Conditions: Metastatic Breast Cancer
Register for Updates
Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants
NCT05547165
Recruiting
Patent Ductus Arteriosus is a developmental condition commonly observed among preterm infants. It is a condition where the opening between the two major blood vessels leading from the heart fail to close after birth. In the womb, the opening (ductus arteriosus) is the normal part of the circulatory system of the baby, but is expected to close at full term birth. If the opening is tiny, the condition can be self-limiting. If not, medications/surgery are options for treatment. There are two ways... Read More
Gender:
ALL
Ages:
Between 7 days and 32 days
Trial Updated:
03/25/2025
Locations: Arkansas Children's Hospital, Little Rock, Arkansas
Conditions: Ductus Arteriosus, Patent
Register for Updates
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
NCT06504589
Recruiting
The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not take CFTR modulators. This data may be used to inform CF research, help design CF clinical trials and support the development of new treatments for people with CF who do not take CFTR modulators. Another goal of this study is to learn about research... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/24/2025
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Cystic Fibrosis
Register for Updates
Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder
NCT05536414
Recruiting
This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-arm trial to assess the efficacy, safety, and tolerability of centanafadine once-daily (QD) extended-release (XR) capsules for the treatment of adult subjects diagnosed with Major Depressive Disorder (MDD). The trial will evaluate the efficacy and safety of centanafadine QD XR capsules as monotherapy or as adjunct to the selective serotonin reuptake inhibitor (SSRI), escitalopram.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/24/2025
Locations: SanRo Clinical Research Group LLC, Bryant, Arkansas
Conditions: Major Depressive Disorder
Register for Updates
Trial of Indication-Based Transfusion of Red Blood Cells in ECMO
NCT05405426
Recruiting
TITRE - Trial of Indication-based Transfusion of Red Blood Cells in ECMO, is a multicenter, prospective, randomized clinical trial. The overarching goal of TITRE is to determine whether restricting red blood cell (RBC) transfusion according to an indication-based strategy for those with bleeding and/or deficit of tissue oxygen delivery, compared with transfusion based on center-specific hemoglobin or hematocrit thresholds, can reduce organ dysfunction and improve later neurodevelopment in critic... Read More
Gender:
ALL
Ages:
Between 0 days and 6 years
Trial Updated:
03/24/2025
Locations: Arkansas Children's Hospital, Little Rock, Arkansas
Conditions: Extracorporeal Membrane Oxygenation, Red Blood Cell Transfusion, Organ Failure, Multiple
Register for Updates
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
NCT04777357
Recruiting
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United States. The treatment of the depressive episodes of bipolar disorder in the pediatric population has not been as widely studied as the treatment of depressive episodes in bipolar disorder in adults, therefore pharmacotherapeutic options are limited. Given the change in disease state and safety demonstrated in adults with depressive episodes associate... Read More
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
03/24/2025
Locations: Pillar Clinical Research /ID# 226504, Bentonville, Arkansas
Conditions: Depression, Bipolar I Disorder
Register for Updates